MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors
- PMID: 12218132
- DOI: 10.4049/jimmunol.169.6.3146
MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors
Abstract
The structures of alphabeta TCRs bound to complexes of class I MHC molecules and peptide show that the TCRs make multiple contacts with the alpha1 and alpha2 helixes of the MHC. Previously we have shown that the A6 TCR in complex with the HLA-A2/Tax peptide has 15 contact sites on HLA-A2. Single amino acid mutagenesis of these contact sites demonstrated that mutation of only three amino acids clustered on the alpha1 helix (R65, K66, A69) disrupted recognition by the A6 TCR. In the present study we have asked whether TCRs that recognize four other peptides presented by HLA-A2 interact with the MHC in identical, similar, or different patterns as the A6 TCR. Mutants K66A and Q155A had the highest frequency of negative effects on lysis. A subset of peptide-specific CTL also selectively recognized mutants K66A or Q155A in the absence of exogenous cognate peptides, indicating that these mutations affected the presentation of endogenous peptide/HLA-A2 complexes. These findings suggest that most HLA-A2-restricted TCRs recognize surfaces on the HLA-A2/peptide complex that are dependent upon the side chains of K66 and Q155 in the central portion of the peptide binding groove. Crystallographic structures of several peptide/HLA-A2 structures have shown that the side chains of these critical amino acids that make contact with the A6 TCR also contact the bound peptide. Collectively, our results indicate that the generalized effects of changes at these critical amino acids are probably due to the fact that they can be directly contacted by TCRs as well as influence the binding and presentation of the bound peptides.
Similar articles
-
Identification of a crucial energetic footprint on the alpha1 helix of human histocompatibility leukocyte antigen (HLA)-A2 that provides functional interactions for recognition by tax peptide/HLA-A2-specific T cell receptors.J Exp Med. 2001 Mar 5;193(5):551-62. doi: 10.1084/jem.193.5.551. J Exp Med. 2001. PMID: 11238586 Free PMC article.
-
Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes.J Immunol. 2003 Sep 15;171(6):3064-74. doi: 10.4049/jimmunol.171.6.3064. J Immunol. 2003. PMID: 12960332
-
MHC recognition by hapten-specific HLA-A2-restricted CD8+ CTL.J Immunol. 2003 Sep 1;171(5):2233-41. doi: 10.4049/jimmunol.171.5.2233. J Immunol. 2003. PMID: 12928367
-
Structural, biochemical, and biophysical studies of HLA-A2/altered peptide ligands binding to viral-peptide-specific human T-cell receptors.Cold Spring Harb Symp Quant Biol. 1999;64:235-41. doi: 10.1101/sqb.1999.64.235. Cold Spring Harb Symp Quant Biol. 1999. PMID: 11232291 Review. No abstract available.
-
Not just another Fab: the crystal structure of a TcR-MHC-peptide complex.Structure. 1997 Feb 15;5(2):159-63. doi: 10.1016/s0969-2126(97)00175-5. Structure. 1997. PMID: 9032079 Review.
Cited by
-
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.J Immunol. 2005 Apr 15;174(8):4812-20. doi: 10.4049/jimmunol.174.8.4812. J Immunol. 2005. PMID: 15814707 Free PMC article.
-
Charge-based interactions through peptide position 4 drive diversity of antigen presentation by human leukocyte antigen class I molecules.PNAS Nexus. 2022 Jul 27;1(3):pgac124. doi: 10.1093/pnasnexus/pgac124. eCollection 2022 Jul. PNAS Nexus. 2022. PMID: 36003074 Free PMC article.
-
An alternative to current thinking about positive selection, negative selection and activation of T cells.Immunology. 2004 Apr;111(4):375-80. doi: 10.1111/j.0019-2805.2004.01830.x. Immunology. 2004. PMID: 15056372 Free PMC article. Review.
-
A Peptide Vaccine Design Targeting KIT Mutations in Acute Myeloid Leukemia.Pharmaceuticals (Basel). 2023 Jun 27;16(7):932. doi: 10.3390/ph16070932. Pharmaceuticals (Basel). 2023. PMID: 37513844 Free PMC article.
-
Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.Mol Immunol. 2010 Sep;47(15):2519-24. doi: 10.1016/j.molimm.2010.06.005. Epub 2010 Jul 8. Mol Immunol. 2010. PMID: 20619457 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials